 Avalon GloboCare Corp NASDAQ:ALBT revealed that it has deployed a breakthrough fusion gene map technology to be used for the goal of developing companion diagnostic kits and devices to enhance personalized clinical management of leukemia patients. The Freehold, New Jersey-based biotechnology company is enabling the development and commercialization of companion diagnostics and novel therapeutic targets for leukemia patients. 